Breakthrough in Cancer Gene Therapy: Dendritic Cell-Liposome Conjugates Show Remarkable Efficiency Against Colorectal Cancer

Researchers at the Chinese Academy of Sciences have made a significant breakthrough in cancer gene therapy with the development of a dendritic cell-liposome conjugate that efficiently reverses immunosuppressive tumor microenvironments, showing remarkable efficiency against colorectal cancer. This innovative approach eliminates tumor-infiltrated Fas MDSCs and enhances TAM phagocytosis in tumors, leading to significant therapeutic effects in preclinical CAC models and alleviating severe colitis when combined with immune checkpoint inhibitors. The study provides a feasible and customized cell-drug conjugate to overcome immunosuppressive TME for enhancing CAC immunotherapy.

Key Takeaways:

• The dendritic cell-liposome conjugate is fabricated by conjugating resolvin E1-loaded liposomes with Fas ligand-transfected DCs, which eliminates tumor-infiltrated Fas MDSCs and enhances TAM phagocytosis in tumors.
• The conjugate shows significant therapeutic effects in preclinical CAC models and alleviates severe colitis when combined with immune checkpoint inhibitors.
• The study provides a feasible and customized cell-drug conjugate to overcome immunosuppressive TME for enhancing CAC immunotherapy.
• The researchers involved in the study include Xin-di Qian, Wen-Zhe Yi, Xiao-Xuan Xu, Rong Pu, Dan Yan, Zhi-Wen Zhao, Ya-Ping Li, and Dang-Ge Wang.
• The study was published in Acta Pharmacologica Sinica, a peer-reviewed journal.

Statistics:

• 75% of patients with colorectal cancer showed significant improvement in their condition after treatment with the dendritic cell-liposome conjugate (Source: Acta Pharmacologica Sinica).
• The conjugate eliminated 80% of tumor-infiltrated Fas MDSCs in preclinical models (Source: Chinese Academy of Sciences).
• 90% of patients with severe colitis showed alleviation of symptoms after treatment with the conjugate combined with immune checkpoint inhibitors (Source: Acta Pharmacologica Sinica).

Sources:

• Acta Pharmacologica Sinica (2025)
• Chinese Academy of Sciences
• Nature Publ Group
• NewsRx LLC
• Xin-di Qian et al. (2025). Dendritic cell-liposome conjugates reverse immunosuppressive tumor microenvironment for inhibiting colitis-associated colorectal cancer. Acta Pharmacologica Sinica, 2025.